,"Product (company, year of approval, disease)",Revenue in million U.S. dollars
0,"Stelara (Janssen, 2015, CD)",399.5
1,"Xeljanz (Pfizer, 2017, UC)",101.0
2,"Vercimon (ChemoCentryx, 2019, CD)",93.6
3,"Kappaproct (InDeX Pharmaceuticals, 2014, UC)*",47.0
